Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 20,854 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Suspended Not applicable Interventional

Efficacy of a Non-invasive Vestibular System Masking for Improving Outcomes Following Acute Unilateral Vestibulopathy

NCT04226976
View directory record Official record
Conditions
Dizziness, Nausea
Interventions
Otoband, Placebo Device
Device
Lead sponsor
Otolith Labs
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients

NCT03131817
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Medtronic Activa PC+S System with Chronic Neural Recording, Effort-Reward Decision-Making Task, Prefrontal Cortex Stimulation, Tablet-Based Mood Tracking (Immediate Mood Scaler)
Device · Behavioral · Other
Lead sponsor
Simon J. Little, MBBS, PhD
Other
Eligibility
30 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 14, 2026, 5:58 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Evaluation of Lymphatic Response to Physiotherapy in Patients With Swelling Associated With Superficial Venous Disease

NCT07165340
View directory record Official record
Conditions
Chronic Venous Disease
Interventions
Indocyanine Green near infrared fluorescence imaging, advanced pneumatic compression, Duplex ultrasound, compression wrap
Combination Product · Device · Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

NCT03177291
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
Interventions
Pirfenidone, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 14, 2026, 5:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Adaptability of an Undetectable = Untransmissible Model for HBV

NCT07449091
View directory record Official record
Conditions
Chronic Hepatitis b, Viremia
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Yoga in Older Cardiac Patients

NCT06235658
View directory record Official record
Conditions
Cardiovascular Diseases in Old Age
Interventions
Gentle Yoga
Behavioral
Lead sponsor
Geunyeong Cha
Other
Eligibility
65 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Active, not recruiting Phase 3 Interventional

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

NCT03040778
View directory record Official record
Conditions
Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions
Pentoxifylline, Placebo, Tocopherol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Terminated Phase 1 Interventional

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Momelotinib, Best Available Therapy (BAT)
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion

NCT01059474
View directory record Official record
Conditions
Toxicity
Interventions
transdermal DMPS
Drug
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 14, 2026, 5:58 AM EDT
Recruiting No phase listed Observational

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

NCT06401889
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

NCT06195891
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Dual-Energy Computed Tomography, Echocardiography, Fludarabine, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Tacrolimus, Thiotepa, Total Marrow and Lymphoid Irradiation
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Not listed Phase 2 Interventional

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00042913
View directory record Official record
Conditions
Lymphoma
Interventions
epratuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Stem Cell Transplantation to Treat Systemic Mastocytosis

NCT00006413
View directory record Official record
Conditions
Mastocytosis
Interventions
Stem cell transplantation
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 5:58 AM EDT
Recruiting Phase 3 Interventional

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab SC, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Investigation of Laser Assisted Drug Delivery of NanoDOX®

NCT05411484
View directory record Official record
Conditions
Wounds and Injury
Interventions
NanoDOX® Hydrogel, CO2 Ablative Fractional Laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT01062152
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Ezatiostat Hydrochloride, Lenalidomide (Revlimid®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Maywood, Illinois • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RCT: Can a Single Counseling Phone Call Improve Contraception After an Abortion?

NCT01199952
View directory record Official record
Conditions
Contraception
Interventions
Treatment group: receives counseling phone call intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years and older · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 14, 2026, 5:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

NCT03516708
View directory record Official record
Conditions
Rectal Cancer
Interventions
Epacadostat, Short-course radiation therapy, CAPOX chemotherapy, FOLFOX chemotherapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 3 Interventional

Voriconazole to Treat Fungal Infections

NCT00001940
View directory record Official record
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Not applicable Interventional

Exercise Training Study for Patients With Cystic Fibrosis

NCT00609050
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Self-Regulated Exercise with Telephone Reinforcement, Standard Treatment, Qualitative Approach
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
10 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 14, 2026, 5:58 AM EDT
Terminated Phase 1 Interventional Results available

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

NCT02795819
View directory record Official record
Conditions
Renal Cell Carcinoma, Soft Tissue Sarcoma, Metastatic Disease
Interventions
AR-42, Pazopanib
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

NCT01178892
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Placebo, Omega-3, Yoga, Exercise, Usual Activity
Dietary Supplement · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Therapeutic Diets in Alzheimer's Disease

NCT03860792
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Ketogenic Diet, Therapeutic Lifestyles Changes Diet
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 5:58 AM EDT